ANZAN VIRTUAL 2021 FOREFRONTS— Handbook and MOVING ON Abstracts 19 – 21 May 2021 ASM anzan2021.com Hosted By Australian and New Zealand Association of Neurologists (ANZAN) 145 Macquarie Street Sydney NSW 2000 P: +61 2 9169 4893 E: [email protected] W: www.anzan.org.au ANZAN Executive Officer Ms Mandy Jones ANZAN Scientific Contents Program Committee Kaitlyn Parratt (Chair) ANZAN — Host Organisation 1 Rebekah Ahmed Scientific Program Committee 1 Andrew Bleasel Amy Brodtmann Meeting Organiser 1 Jim Burrow Welcome 3 Bruce Campbell Sponsors 5 Michael Dreyer Robert Henderson International Keynote Speakers 11 Jeannette Lechner-Scott Invited Speakers 14 Debbie Mason Awards 26 Carolyn Orr Carolyn Sue Program Information 31 Ian Wilson Daily Program and Abstracts 32 Wednesday, 19 May 33 Meeting Organiser Thursday, 20 May 62 Friday, 21 May 73 Poster Abstracts 78 Poster Listing 146 P: +61 4 2382 7488 (Lejla) P: +61 4 1884 1154 (Cathy) P: +61 4 0028 0811 (Janine) E: [email protected] W: www.anzan2021.com PO Box 2137 Glenelg SA 5045 1 Biogen Australia Pty Ltd, ABN: 30 095 760 115, Macquarie Park NSW 2113. Biogen NZ Biopharma Limited, 188 Quay Street, Auckland, New Zealand. ©Biogen is a registered trademark of Biogen MA Inc. ©2021. Biogen-106663. BIOG0911/EMBC. Date of preparation: April 2021. Welcome Welcome to the ANZAN Annual Scientific Meeting! This year’s meeting is a first for ANZAN – the meeting will be delivered online. While this change has been a response to the travel restrictions of the pandemic, it also gives us a chance to try something new. It can’t be denied that an online meeting has advantages in terms of time saving and reduced carbon footprint. This year, the meeting has the theme “Virtual Forefronts”. The ANZAN Scientific Programme Committee has produced an exciting programme that includes talks at the cutting edge of neurological practice. Kaitlyn Parratt and the committee has embraced the challenge of running a virtual meeting and have selected an impressive range of talks from the abstracts submitted by the members. We are grateful for their efforts. The program has undergone some last-minute changes. Unfortunately, due to personal commitments Professor Roos is no longer able to participate in our meeting this year. We wish her all the best at this time. Thankfully, due to the generosity of four renowned International and National speakers the program has not been compromised. Dr Nicolas Davies and Professor Tom Solomon will join us from the United Kingdom to discuss Neurology and COVID and Emerging Brain Infections. Dr Joshua Davis, Infectious Disease Physician from Newcastle will share his clinical pearls in Neuroinfectious disease, and Dr Tim Kleinig will provide a cutting edge update related to COVID vaccination complications. We also will have a full complement of ANZAN awards – the EG Robertson Award will be delivered by Christian Lueck, the JW Lance oration will be delivered by Ingrid Sheffer, the Mervyn Eadie lecture will be given by Mark Cook, the Ian McDonald lecture by Ernie Willoughby, the Leonard Cox award for 2020 by Rebekah Ahmed and the Leonard Cox award for 2021 by Piero Perucca. These speakers are all experts in their fields and ANZAN is proud to have such distinguished members to receive these awards. I would like to thank our sponsors for their strong ongoing support of ANZAN. I encourage everyone to support the exhibitors. Please enjoy this year’s Annual Scientific Meeting, which will showcase the scholarship and expertise of the ANZAN membership and will provide invaluable educational update. For all the latest information on the Conference, visit Pamela McCombe anzan2021.com President, ANZAN 3 NOW PBS LISTED1 Make treatment an easy part of life:2–4 › New once-daily oral S1P › No first dose monitoring receptor modulator2 or genetic testing2 › Effectively reduces disease › Generally well tolerated†3,4 activity in RMS*2–4 * Significantly reduced annualised relapse rates and lesion activity (mean number of GdE lesions and new/enlarging T2 lesions) vs IFN ß-1a IM (p <0.001)2–4 † Only ~3% of ZEPOSIA patients in Phase III studies discontinued due to adverse events3,4 PBS Information: Authority required (STREAMLINED). For use in patients with relapsing-remitting multiple sclerosis who meet certain criteria. Refer to PBS Schedule for full authority information. Before prescribing, please review the Product Information click here. Abbreviations: GdE: gadolinium-enhancing. IFN ß-1a: interferon beta-1a. IM: intramuscular. PBS: Pharmaceutical Benefits Scheme. RMS: relapsing multiple sclerosis. S1P: sphingosine 1-phosphate References: 1. Pharmaceutical Benefits Scheme. www.pbs.gov.au. 2. ZEPOSIA® Approved Product Information. 3. Comi G et al. Lancet Neurol 2019;18:1009–20. 4. Cohen JA et al. Lancet Neurol 2019;18:1021–33. ZEPOSIA® is a registered trademark of Celgene Corporation. Celgene Pty Limited Australia. Level 15, 60 City Road, Southbank, VIC 3006. ABN 42 118 998 771. Date of preparation: April 2021. 2084-AU-2100121. BMMS21493W. Ward6. Thank you to our Sponsors The Organising Committee of the Australian and New Zealand Association of Neurologists Annual Scientific Meeting 2021 gratefully acknowledges the support of the following Sponsors: Gold Sponsor Biogen Australia At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain. For more information, please visit www.biogen.com.au or www.biogen.co.nz Company Contact | Fiona Tigar | [email protected] | +61 400 741 286 Gold Sponsor Bristol Myers Squibb Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. The Bristol Myers Squibb Foundation, an independent charitable organization, promotes health equity and seeks to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Company Contact | Clare Cipa | [email protected] | 0409 862 055 5 Thank You to Our Sponsors Gold Sponsor Merck Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees (in 66 countries) work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Gold Sponsor Novartis Pharmaceuticals Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. We believe continued R&D is essential to innovation and in Australia last year we invested 20M in clinical trials. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Novartis has more than 60 years’ history in Australia and employ around 600 across its two divisions. For more information, please visit http://www.novartis.com.au Company Contact | Danijel Jurkovic | [email protected] 6 Thank You to Our Sponsors Gold Sponsor Roche Products Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics have made Roche the leader in personalised healthcare – aims to boldly transform and personalise healthcare to prevent, diagnose and treat each and every patient more effectively, while creating a more sustainable healthcare ecosystem. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology,